Overall, our study shows that DNMT3A R882 mutations confer unique clinicopathologic features with an increased risk of AML transformation in MDS, which is modified by the coexisting SF3B1 or SRSF2 mutations. Here, SRSF2 is linked to acute myeloid leukemia.